WO2008146854A1 - Paratope et épitope d'anticorps d'anti-mortaline - Google Patents

Paratope et épitope d'anticorps d'anti-mortaline Download PDF

Info

Publication number
WO2008146854A1
WO2008146854A1 PCT/JP2008/059834 JP2008059834W WO2008146854A1 WO 2008146854 A1 WO2008146854 A1 WO 2008146854A1 JP 2008059834 W JP2008059834 W JP 2008059834W WO 2008146854 A1 WO2008146854 A1 WO 2008146854A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
mortalin
epitope
chain
paratope
Prior art date
Application number
PCT/JP2008/059834
Other languages
English (en)
Japanese (ja)
Inventor
Renu Wadhwa
Sunil Kaul
Maki Shiota
Atsushi Inoue
Original Assignee
National Institute Of Advanced Industrial Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2008036343A external-priority patent/JP5142265B2/ja
Application filed by National Institute Of Advanced Industrial Science And Technology filed Critical National Institute Of Advanced Industrial Science And Technology
Priority to US12/602,358 priority Critical patent/US8591893B2/en
Publication of WO2008146854A1 publication Critical patent/WO2008146854A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pour un anticorps d'anti-mortaline d'internalisation cellulaire et un anticorps d'anti-mortaline non internalisant, la détermination de la séquence d'acides aminés d'un domaine de paratope situé dans une région variable de chacune des chaînes L et H et impliquée dans l'internalisation d'un anticorps d'anti-mortaline dans une cellule tumorale est déterminée. Un anticorps monocaténaire (scFv) portant, relié à celui-ci par l'intermédiaire d'un lieur peptidique, une région variable de chacune des chaînes L et H transportant le domaine de paratope et un apport de médicament spécifique à une cellule cancéreuse, est fourni en exploitant une capacité de liaison de l'anticorps monocaténaire à la mortaline. En outre, relativement à un paratope qui peut être reconnu par un anticorps d'anti-mortaline constitué de 6 résidus d'acides aminés et ayant une activité d'internalisation, la séquence d'acides années de l'épitope est déterminée. En utilisant un vecteur d'expression transportant un acide nucléique codant l'épitope, il devient possible de fournir un agent permettant de promouvoir l'internalisation d'un anticorps d'anti-mortaline, substance conjuguée à l'anticorps d'anti-mortaline ou analogue, dans une cellule cancéreuse.
PCT/JP2008/059834 2007-05-28 2008-05-28 Paratope et épitope d'anticorps d'anti-mortaline WO2008146854A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/602,358 US8591893B2 (en) 2007-05-28 2008-05-28 Paratope and epitope of anti-mortalin antibody

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007-140943 2007-05-28
JP2007140943 2007-05-28
JP2007296405 2007-11-15
JP2007-296405 2007-11-15
JP2008-036343 2008-02-18
JP2008036343A JP5142265B2 (ja) 2007-05-28 2008-02-18 抗モータリン抗体のパラトープ及びエピトープ

Publications (1)

Publication Number Publication Date
WO2008146854A1 true WO2008146854A1 (fr) 2008-12-04

Family

ID=40075091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059834 WO2008146854A1 (fr) 2007-05-28 2008-05-28 Paratope et épitope d'anticorps d'anti-mortaline

Country Status (1)

Country Link
WO (1) WO2008146854A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071099A1 (fr) * 2009-12-10 2011-06-16 独立行政法人産業技術総合研究所 Anticorps anti-peptide de mortaline anticancéreux
WO2012057328A1 (fr) * 2010-10-29 2012-05-03 株式会社ペルセウスプロテオミクス Anticorps anti-cdh3 présentant une capacité élevée d'internalisation
EP2700652A4 (fr) * 2011-04-18 2015-07-15 Univ Tokyo Diagnostic et traitement du cancer à l'aide d'un anticorps anti-itm2a
WO2017037707A1 (fr) * 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps spécifiques contre le domaine d'immunoglobuline de lymphocyte t et itim (tigit)
EP3221350A4 (fr) * 2014-11-20 2018-08-08 Ramot at Tel-Aviv University Ltd. Peptides de mortaline et anticorps anti-mortaline et leurs utilisations pour inhiber l'activité mortaline et traiter une maladie associée à une cellule pathologique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500084A (ja) * 1992-05-11 1996-01-09 イムノメディクス，インコーポレイテッド 毒素および薬剤を含む治療用複合体
JP2005500808A (ja) * 2000-12-06 2005-01-13 ニユーララブ・リミテツド βアミロイドペプチドを認識するヒト化抗体
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500084A (ja) * 1992-05-11 1996-01-09 イムノメディクス，インコーポレイテッド 毒素および薬剤を含む治療用複合体
JP2005500808A (ja) * 2000-12-06 2005-01-13 ニユーララブ・リミテツド βアミロイドペプチドを認識するヒト化抗体
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BESPALOV I.A. ET AL.: "Recombinant Phabs reactive with 7,8-dihydro-8-oxoguanine, a major oxidative DNA lesion", BIOCHEMISTRY, vol. 35, no. 7, 1996, pages 2067 - 2078 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586042B2 (en) 2009-12-10 2013-11-19 National Institute Of Advanced Industrial Science And Technology Hybridomas producing monoclonal anti-mortalin peptide antibodies
WO2011071099A1 (fr) * 2009-12-10 2011-06-16 独立行政法人産業技術総合研究所 Anticorps anti-peptide de mortaline anticancéreux
EP2511371A1 (fr) * 2009-12-10 2012-10-17 National Institute of Advanced Industrial Science And Technology Anticorps anti-peptide de mortaline anticancéreux
EP2511371A4 (fr) * 2009-12-10 2013-05-15 Nat Inst Of Advanced Ind Scien Anticorps anti-peptide de mortaline anticancéreux
US9328160B2 (en) 2010-10-29 2016-05-03 Perseus Proteomics Inc. Anti-CDH3 antibody having high internalization capacity
WO2012057328A1 (fr) * 2010-10-29 2012-05-03 株式会社ペルセウスプロテオミクス Anticorps anti-cdh3 présentant une capacité élevée d'internalisation
JP2016175945A (ja) * 2010-10-29 2016-10-06 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
JP6006640B2 (ja) * 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
EP2700652A4 (fr) * 2011-04-18 2015-07-15 Univ Tokyo Diagnostic et traitement du cancer à l'aide d'un anticorps anti-itm2a
US9920129B2 (en) 2011-04-18 2018-03-20 The University Of Tokyo Diagnosis and treatment of cancer using anti-ITM2A antibody
EP3221350A4 (fr) * 2014-11-20 2018-08-08 Ramot at Tel-Aviv University Ltd. Peptides de mortaline et anticorps anti-mortaline et leurs utilisations pour inhiber l'activité mortaline et traiter une maladie associée à une cellule pathologique
WO2017037707A1 (fr) * 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticorps spécifiques contre le domaine d'immunoglobuline de lymphocyte t et itim (tigit)
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
US12121579B2 (en) 2015-09-02 2024-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)

Similar Documents

Publication Publication Date Title
WO2009073533A3 (fr) Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
PH12018501850A1 (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
WO2006099141A3 (fr) Anticorps diriges contre la mesotheline
WO2009130575A3 (fr) Anticorps monoclonal isolé ou fragment de celui-ci se liant à l'antigène membranaire spécifique de la prostate, ses conjugués et utilisations
WO2011159847A3 (fr) Conjugués du fragment d'anticorps fv à chaîne unique dirigé contre le récepteur orphelin 1 analogue au récepteur à la tyrosine kinase (ror1) et leurs procédés d'utilisation
EA201270620A1 (ru) Антитела к интегрину, связанные с наночастицами, содержащими химиотерапевтические агенты
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
WO2008074004A3 (fr) Anticorps humains se liant à cd70 et utilisations de ceux-ci
EP2509627A4 (fr) Méthodes d'amplification d'un traitement à base d'anticorps anticancéreux
GEP20115226B (en) P-cadherin antibodies
NZ602220A (en) Antibodies with ph dependent antigen binding
AR064109A1 (es) Anticuerpos humanos que se enlazan al cd22 y sus usos
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
IL193986A (en) Isolated or part of an antibody selectively associated with human antigen 4t 5, antibody / drug delivery agent, use of this agent for drug preparation and host cell expressing isolated nucleic acid encoded for a heavy and light 5t4 antibody chain
WO2010019702A3 (fr) Agents de liaison à ddr1 et leurs méthodes d'utilisation
WO2008076560A3 (fr) Anticorps monoclonaux humains contre le btla et procédés d'utilisation
WO2009140177A3 (fr) Anticorps anti-fn14 et leurs utilisation
WO2006121422A3 (fr) Anticorps diriges contre des toxines de clostridium difficile et utilisations de ces derniers
WO2006050834A3 (fr) Anticorps vis-a-vis de la tenascine-c
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
WO2009088805A3 (fr) Ciblage d'anticorps par domaine de reconnaissance modulaire
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
WO2005115477A3 (fr) Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776949

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776949

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12602358

Country of ref document: US